NCT06792734View on ClinicalTrials.gov

Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 14, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

December 31, 2027

Conditions
Lymphoma, B-Cell
Interventions
DRUG

BTM-3566

Oral Solution

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

Bantam Pharmaceuticals

INDUSTRY

NCT06792734 - Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas | Biotech Hunter | Biotech Hunter